Maria Pia Sormani, PhD, University of Genoa, Genoa, Italy, talks on issues related to COVID-19 data interpretation coming from multiple sclerosis (MS) registries. One of the challenges is comparing data from different registries. Dr Pia Sormani gives the example of comparing COVID-19 outcomes across different countries. This happens not only because COVID-19 is managed differently in different countries but also because the outcome collection is performed differently. Therefore, data comparisons between registries should be made carefully. An updated analysis was carried out on the Italian registry looking only at confirmed COVID-19 cases to review the results common to most registries. Results from this analysis indicate that there’s a higher risk for severe disease in patients with MS treated with anti-CD20 therapies, while there seems to be a protective role of interferon-beta. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress 2021.
Dr Sormani reports the following disclosures:
Consulting fees from Biogen, Roche, Novartis, Sanofi, Merck, Immunic, Geneuro, and GSK.